developed rutin-loaded polydopamine nanoparticles (PEG-PDA@rutin NPs) to eliminate ROS and inhibit ferroptosis
AOD-9604 hasdemonstratedpotent lipolytic activity without impacting glucose levels, tissue growth, or inducing overeating
Several mechanisms might explain possible benefits: Improved glycaemic control : Better blood glucose regulation may reduce endothelial dysfunction and microvascular damage, both implicated in ED pathophysiology Weight reduction : Significant weight loss can improve testosterone levels, reduce inflammation, and enhance vascular function Cardiovascular effects : GLP-1 agents may improve endothelial function and reduce cardiovascular risk factors that contribute to ED Reduced inflammation : These medications have been associated with anti-inflammatory effects that might benefit vascular health, though more research is needed Some observational studies have reported improvements in erectile function scores among men with diabetes treated with GLP-1 receptor agonists, though the evidence is limited and more robust research is needed
Anti-p70S6K (1:1000, 2217 s) and anti-phospho-p70S6K (Thr 389) (1:1000, 4858 s) were purchased from Cell Signaling Technology (Danvers, MA, USA)
This is only a summary of potential side effects and how to address them